Case study
How Roche diversified international clinical trials through demographic and health variable data
Summary
For international pharmaceutical and diagnostics company, Roche, a core function of the organisation is the running of clinical trials for regulatory approval of new medications. In particular, the insights and analytics team is involved in supporting late-stage trials by identifying the most appropriate hospital locations and clinical trial patients for these trials across countries, to enable the most effective recruitment process.
Company size
10,000+
Industry
Healthcare
Products Used
Challenge
Diversity
Historically, clinical trial populations have often differed from the populations that use the medications, resulting in clinical trial patients being predominantly Caucasian and coming from more affluent socioeconomic backgrounds.
Regulation
Regulations are evolving and regulatory agencies are driving a new view on diversity and inclusion in clinical trials.
Data
Lack of data availability, legal barriers, data collection and protection and privacy issues are all common hurdles in clinical trials, especially in Europe.
Solution
By working with CACI, Roche’s insights and analytics team has used a combination of demographic and health variable data within CACI’s analytical and mapping tool, InSite, to determine locations that would best suit the recruitment of more diverse populations for clinical trials in five European markets.
With diversifying clinical trials being the team’s goal, the key variables it needed to understand included ethnicity, deprivation, education attainment, economic status, rural versus urban, smoking, pollution and other disease risk factors. CACI developed bespoke models for these variables by combining key demographics such as age, income and gender with survey data on a country-by-country basis to generate models at a postcode level for each of the required countries.
Results
Roche’s insights and analytics team has benefitted from CACI’s bespoke model and expertise, delivering the model to the team and providing training on how to use it. The team has since been able to use data-driven decision making to tackle any clinical trial strategy obstacles versus relying on assumption.
Having previously worked with CACI on smaller, UK-focused projects, the ability to now take this bespoke model to scale so that it can be accessed across other countries has augmented Roche’s diversity strategy. The team has been particularly pleased by CACI’s quick data generation and innovation in terms of modelled data from survey data sources.
